SecBot SecBot

INTS

INTENSITY THERAPEUTICS, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001567264 Biotech & Drug Discovery
$3.20 −0.05 (−1.54%)
Oct 26 4:00 PM ET · prev $3.25
Market cap
$10.4M
Nano cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
🔒 Subscribers only
1 year
−47.5%
from $6.10 · Oct 27
30 days
−12.3%
from $3.65
52-week range
$3.14–33.00
−90% from high · low Oct 21
Avg volume 20D
22.5K
Oct 13 spike 123.7K
Short interest
38.3K
≈1.2% of shares · +22.2%
Days to cover
2.1
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score
Strongest NEUTRAL Intensity Therapeutics reported Q2 2026 results with a net loss of $3.0M, wider than the $2.5M loss in Q2…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • X Jul 15 Short interest jumps 28.6% to 162.6K
  • X Jul 31 Short interest falls 58.0% to 68.4K
  • X Aug 31 Short interest falls 40.2% to 48.9K
  • X Sep 15 Short interest falls 36.0% to 31.3K

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +22.2% to 38.3K shares. 2.1 days to cover, ≈1.2% of shares.

  • TrendDOWNTREND

    17% below its 50-day average. New closing low $3.14 on Oct 21.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD26,569$108.9K
UBS Group AGNEAR_EXIT1$4.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy2Buy8Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 18, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 8, 2026
Press release
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SHELTON, Conn., Sept. 8, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical…
Aug 4, 2026
Earnings
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Company to hold a conference call at 8AM ET on August 11, 2026 to review results and provide a corporate update SHELTON, Conn., Aug. 4, 2026…
May 7, 2026
Earnings date
INTS Q1 2026 Earnings Scheduled — 2026-05-07
Mar 12, 2026
Earnings date
INTS Q4 2025 Earnings Scheduled — 2026-03-12

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 16, 2026
BENDER LEWIS H
President and CEO
AWARD78,000 sh
Jul 16, 2026
DUBIN THOMAS I H
Director
AWARD5,500 sh
Jul 16, 2026
Wesolowski John M
Principal Accounting Officer
AWARD11,000 sh
Jul 16, 2026
GOLDBERG MARK A
Director
AWARD5,500 sh
Jul 16, 2026
Donovan Daniel
Director
AWARD5,500 sh
Jul 16, 2026
Talamo Joseph
Chief Financial Officer
AWARD34,000 sh
Jul 16, 2026
Leahy Emer
Director
AWARD5,500 sh
Jun 30, 2026
Talamo Joseph
Chief Financial Officer
AWARD$3.8K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
38,253
shares short
+22.2%
vs prior settlement
2.1
days to cover
≈1.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 8, 2026 Other
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SHELTON, Conn., Sept. 8, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensit
Aug 11, 2026 SEC
Intensity Therapeutics reported Q2 2026 results with a net loss of $3.0M, wider than the $2.5M loss in Q2 2025, and…
8-K — Impact 5/10
Jul 16, 2026 Insider
BENDER LEWIS H was granted 78,000 shares
President and CEO
Jul 16, 2026 Insider
DUBIN THOMAS I H was granted 5,500 shares
Director
Jul 16, 2026 Insider
Wesolowski John M was granted 11,000 shares
Principal Accounting Officer
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
26,569 shares ($108.9K)
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
1 shares ($4.00)
Mar 5, 2026 SEC
Intensity Therapeutics updated its investor presentation with unaudited financial highlights for the year ended…
8-K — Impact 3/10

SecBot reports

2 filings · 0 bullish · 0 bearish · 2 neutral
All INTS filing & press-release reports (2)